CNSP - CIK 0001729427
The table below shows CNS Pharmaceuticals, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.20M | $6.46M | $548.72K | $10.06M | $5.00M | $14.04M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.10M |
| $8.66M |
| $1.59M |
| $12.56M |
| $7.48M |
| $15.50M |
| Property, plant & equipment | $17.70K | $6.00K | $4.93K | $5.66K | $16.11K | $23.43K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $8.62M | $8.70M | $1.70M | $13.05M | $8.76M | $15.85M |
| Accounts payable | - | - | - | $3.68M | $1.52M | $946.33K |
| Total current liabilities | $4.10M | $2.52M | $6.13M | $4.92M | $2.14M | $1.91M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $4.10M | $2.52M | $6.13M | $4.92M | $2.14M | $1.91M |
| Retained earnings | -$100.28M | -$84.42M | -$69.57M | -$50.72M | -$34.98M | -$20.95M |
| Total equity | $4.52M | $6.18M | -$4.43M | $8.13M | $6.62M | $13.95M |